The system divides patients into good, intermediate, and poor prognosis groups based on the primary site, pretreatment tumor marker levels (AFP and beta-human chorionic gonadotropin), serum lactate dehydrogenase (LDH) levels, and disease severity. This evidence concerns the gene AFP and neoplasm.